Bli medlem
Bli medlem

Du är här

2016-12-21

Actelion Pharmaceuticals Ltd: Actelion and Johnson & Johnson enter into exclusive discussions

Actelion Pharmaceuticals Ltd / Actelion and Johnson&Johnson enter into
exclusive discussions . Processed and transmitted by Nasdaq Corporate
Solutions.The issuer is solely responsible for the content of this
announcement.
ALLSCHWIL, SWITZERLAND - 21 December 2016 -
Actelion (SIX: ATLN) has entered into exclusive negotiations with
Johnson&Johnson regarding a possible strategic transaction.

There can be no assurance any transaction will result from these discussions.
Actelion does not intend to make any additional comments regarding these
discussions unless and until it is appropriate to do so, or a formal
agreement has been reached.

###

NOTES TO EDITOR

ACTELION LTD

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery,
development and commercialization of innovative drugs for diseases with
significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH).
Our portfolio of PAH treatments covers the spectrum of disease, from WHO
Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous
medications. Although not available in all countries, Actelion has treatments
approved by health authorities for a number of specialist diseases including
Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in
patients suffering from systemic sclerosis, and mycosis fungoides type
cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,500 dedicated professionals covering all
key markets around the world including Europe, the US, Japan, China, Russia
and Mexico, Actelion has its corporate headquarters in Allschwil / Basel,
Switzerland.

Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as
part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All
trademarks are legally protected.

For further information please contact:

Andrew C. Weiss
Senior Vice President, Head of Investor Relations&Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62

http://www.actelion.com

The above information contains certain "forward-looking statements", relating
to the company's business, which can be identified by the use of
forward-looking terminology such as "estimates", "believes", "expects",
"may", "are expected to", "will", "will continue", "should", "would be",
"seeks", "pending" or "anticipates" or similar expressions, or by discussions
of strategy, plans or intentions. Such statements include descriptions of the
company's investment and research and development programs and anticipated
expenditures in connection therewith, descriptions of new products expected
to be introduced by the company and anticipated customer demand for such
products and products in the company's existing portfolio. Such statements
reflect the current views of the company with respect to future events and
are subject to certain risks, uncertainties and assumptions. Many factors
could cause the actual results, performance or achievements of the company to
be materially different from any future results, performances or achievements
that may be expressed or implied by such forward-looking statements. Should
one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated or expected.

Press release PDF
http://hugin.info/131801/R/2067118/776171.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.